查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008444

藥物動力學服務市場：按類型、服務類型和最終用戶分類－2026-2032年全球預測

Pharmacokinetics Services Market by Type, Service Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年藥物動力學服務市場價值 13 億美元，預計到 2026 年將成長至 14.1 億美元，複合年成長率為 9.34%，到 2032 年將達到 24.3 億美元。

主要市場統計數據
基準年 2025 13億美元
預計年份：2026年 14.1億美元
預測年份 2032 24.3億美元
複合年成長率 (%) 9.34%

概述藥物動力學服務調查方法在現代藥物發現的基礎和策略重要性。

藥物動力學服務是現代藥物發現和開發的重要支柱，它提供了將分子特性與臨床結果聯繫起來的定量基礎。本導言將藥物動力學定位為交叉學科領域，它整合了分析化學、生物分析、建模和體內實驗，以闡明藥物的吸收、分佈、代謝和排泄過程。透過了解候選藥物在生物系統中的行為，藥物動力學指導臨床前和臨床給藥策略、安全性評估以及轉化決策。

技術進步、治療方法多樣化以及監管期望的變化正在重塑醫療服務提供者的能力和科學合作的性質。

受技術進步、治療方法轉變和監管要求變化的驅動，藥物動力學服務領域正經歷著變革性的轉變。生物分析儀器的創新，例如質譜靈敏度的提高和樣品處理的自動化，正在縮短檢測週期並擴大可可靠定量分析的化合物範圍。同時，生物製藥、基因療法和核酸藥物的興起，迫使服務供應商開發與標準小分子工作流程顯著不同的專用檢測方法和基質處理能力。

由於 2025 年關稅變化給供應鏈帶來了越來越大的壓力，並增加了跨境複雜性，業務永續營運和籌資策略變得越來越重要。

2025年美國關稅政策和貿易趨勢的變化將對藥物動力學服務生態系統產生多方面的影響，主要體現在供應鏈和成本管道方面，而非直接的科學影響。許多服務供應商依賴進口原料、特殊試劑和昂貴的設備零件。這些投入品關稅的增加可能會增加採購的複雜性，並促使企業重新評估籌資策略。為此，各機構可能會考慮增加庫存緩衝、認證替代供應商或轉向區域採購網路，以維持營運的連續性。

基於細分的詳細洞察，揭示了每種產品類型、服務方法和客戶畫像的不同分析需求和交付模式。

細分市場分析揭示了跨產品類型、服務形式和最終用戶類別的服務開發和客戶參與路徑清晰可見。按類型分類，市場被分為“高分子量藥物動力學服務”和“低分子量藥物動力學服務”，突顯了二者不同的分析需求。高分子量藥物動力學需要開發免疫檢測、配體結合分析以及專門的樣品處理方法來解決穩定性和基質效應問題，而低分子量藥物動力學通常採用高解析度質譜和經驗證的層析法。基於服務類型，市場進一步細分為“體外”和“體內”，表明體外ADME和穩定性測試通過提供早期候選化合物篩選和了解清除途徑機制的信息，對體內藥物動力學研究起到了補充作用。市場分析按最終用戶細分，重點關注學術和政府研究機構、生物技術公司、受託研究機構(CRO) 和製藥公司，表明客戶需求範圍從探索性和假設主導的研究到完全符合 GLP（良好實驗室規範）的研究，涉及監管申報所需的全面文件。

區域競爭優勢和營運考量有助於藥物動力學服務供應商確定在全球何處投資、合作和拓展業務。

區域趨勢影響著美洲、歐洲、中東和非洲以及亞太地區的服務提供、基礎設施投資和合作網路，每個地區都有其獨特的競爭優勢和營運考量。在美洲，生物技術中心和臨床開發中心的集中分佈有利於快速轉化工作流程和醫患密切合作，而監管路徑和支付方環境則影響著北美申辦者對臨床藥理學和資料包的關注。在歐洲、中東和非洲，法規環境的多樣性以及與學術和研究機構的緊密合作促進了跨境合作、多中心試驗以及研究方法的統一檢驗，以滿足不同司法管轄區的要求。

在競爭激烈的環境中，那些整合先進分析技術、跨學科專業知識和以客戶為中心的經營模式，並建立長期夥伴關係的供應商具有優勢。

藥物動力學服務領域的主要企業已從提供簡單檢測的交易型服務發展成為提供涵蓋生物分析、建模和法規支援的綜合性科學夥伴關係的企業。成功的企業透過投資平台自動化、數據完整性系統以及跨職能團隊來脫穎而出，這些團隊能夠將分析結果轉化為可操作的藥物動力學和動態解讀。與儀器製造商和軟體供應商建立策略合作夥伴關係可以提高分析靈敏度和處理能力，而內部開發的標準化報告範本則可以加快法規申報和客戶決策速度。

服務供應商增強科學研究能力、營運韌性和以客戶為中心的商業性框架的實際策略重點。

產業領導企業應優先考慮能夠提升短期內科研能力、營運韌性和客戶協作的切實可行的轉型措施。首先，投資於平台自動化和穩健的生物分析工作流程將有助於縮短週轉時間並提高結果的可重複性，這對於在日益多元化的治療方法保持競爭力至關重要。其次，拓展服務團隊的建模和模擬專業知識將使供應商能夠提供預測性見解，從而輔助劑量選擇和試驗設計，進而為客戶的專案增添戰略價值。

採用透明、多方面的研究途徑，結合專家訪談、文獻整合和情境分析，檢驗藥物動力學服務的趨勢和影響。

本分析的調查方法融合了定性專家訪談、專業文獻綜述以及對技術和監管趨勢的系統評估。關鍵見解來自與藥物動力學專家、臨床藥理學家、實驗室管理人員和採購專家的對話，從而確保對各項技術的能力和局限性有全面的了解。輔助研究包括同行評審文章、監管指導文件和近期技術白皮書，以反映生物分析儀器、建模技術和檢測驗證實踐的最新進展。

概述藥物動力學服務提供者在協調科學創新、營運韌性和以客戶為中心的服務交付方面面臨的策略挑戰。

總之，藥物動力學服務在將分子層面的發現轉化為安全有效的臨床策略方面發揮核心作用，而該領域正在適應技術、治療方法和地緣政治方面的壓力。投資先進生物分析平台、擴展建模和模擬能力以及建立穩健供應鏈的供應商將更有能力滿足學術機構、生物技術公司、合約研究組織 (CRO) 和大型製藥企業的多樣化需求。此外，區域趨勢和關稅相關因素凸顯了靈活採購和近岸外包策略對於維持進度和資料品質的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 藥物動力學服務市場：依類型分類

  • 聚合物藥物動力學服務
  • 小分子藥物動力學服務

第9章 藥物動力學服務市場：依服務類型分類

  • In-Vitro
  • In-Vivo

第10章 藥物動力學服務市場：依最終用戶分類

  • 學術和政府附屬研究機構
  • 生技公司
  • CRO（受託研究機構）
  • 製藥公司

第11章 藥物動力學服務市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 藥物動力學服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 藥物動力學服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國：藥物動力學服務市場

第15章 中國：藥物動力學服務市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Absorption Systems LLC
  • Allucent
  • Aurigene Pharmaceutical Services Ltd.
  • Certara
  • Charles River Laboratories, Inc.
  • Creative Bioarray
  • Eurofins Scientific SE
  • Evotec SE
  • Frontage Laboratories, Inc.
  • ICON PLC
  • Laboratory Corporation of America Holdings
  • LGC Limited by Cinven
  • NUVISAN Pharma Holding GmbH
  • Pacific BioLabs
  • Parexel International（MA）Corporation
  • Pfizer Inc.
  • PPD Inc. by Thermo Fisher Scientific Inc.
  • Premier Consulting
  • Reaction Biology Corporation
  • SGS SA
  • Svar Life Science AB
  • WuXi AppTec Co., Ltd.
  • XenoTech by BioIVT
  • Xyzagen
Product Code: MRR-C002B1C99681

The Pharmacokinetics Services Market was valued at USD 1.30 billion in 2025 and is projected to grow to USD 1.41 billion in 2026, with a CAGR of 9.34%, reaching USD 2.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.30 billion
Estimated Year [2026] USD 1.41 billion
Forecast Year [2032] USD 2.43 billion
CAGR (%) 9.34%

Foundational overview describing the methodological backbone and strategic importance of pharmacokinetics services across modern drug development

Pharmacokinetics services are an integral pillar of contemporary drug discovery and development, providing the quantitative backbone that links molecular properties to clinical outcomes. This introduction frames pharmacokinetics as a multidisciplinary discipline that synthesizes analytical chemistry, bioanalysis, modeling, and in vivo experimentation to characterize absorption, distribution, metabolism, and excretion profiles. By establishing how therapeutic candidates behave in biological systems, pharmacokinetics guides dosing strategies, safety assessments, and translational decision-making across preclinical and clinical stages.

As regulatory expectations rise and therapeutic modalities diversify, pharmacokinetics laboratories have expanded capabilities to support both traditional small molecules and increasingly complex biologics. The convergence of advanced mass spectrometry, high-throughput bioanalytical workflows, and physiologically based pharmacokinetic modeling has improved the precision of exposure-response characterization. Consequently, organizational stakeholders-from bench scientists to program leads-depend on timely, reproducible pharmacokinetic data to de-risk portfolios, optimize trial design, and inform regulatory interactions. This section sets the stage for the deeper analyses that follow by highlighting the methodological foundations, cross-functional importance, and operational pressures shaping services in this sector.

Evolving technology, modality diversity, and regulatory expectations reshaping provider capabilities and collaborative scientific engagement

The pharmacokinetics services landscape is undergoing transformative shifts driven by technological advances, changing modality mixes, and evolving regulatory expectations. Innovations in bioanalytical instrumentation, including increased sensitivity in mass spectrometry and automation of sample processing, are shortening turnaround times and expanding the range of compounds that can be robustly quantified. At the same time, the rise of biologics, gene therapies, and nucleic acid medicines has compelled service providers to develop specialized assays and matrix handling capabilities that differ markedly from standard small molecule workflows.

Moreover, modeling and simulation techniques have matured into strategic decision-support tools. Physiologically based and population pharmacokinetic models are now routinely used to predict human pharmacokinetics from preclinical data, guide first-in-human dose selection, and simulate alternative dosing regimens. In parallel, regulatory agencies increasingly expect integrated PK/PD analyses and transparent modeling reports, prompting providers to embed regulatory-ready documentation into their deliverables. Together, these shifts are reshaping provider-client relationships, prompting deeper scientific collaboration and a focus on flexible, modular service offerings that can accommodate diverse therapeutic modalities and accelerated development timelines.

Operational resilience and procurement strategies becoming critical as tariff changes in 2025 introduce supply chain pressure and cross-border complexities

Changes to tariff policies and trade dynamics in the United States during 2025 have exerted a multifaceted influence on the pharmacokinetics services ecosystem, primarily through supply chain and cost-channel effects rather than direct scientific impact. Many service providers rely on imported raw materials, specialized reagents, and high-value instrumentation components; incremental tariff burdens on these inputs can elevate procurement complexity and prompt re-evaluation of sourcing strategies. In response, organizations may increase inventory buffers, qualify alternative suppliers, or shift to regional procurement networks to preserve operational continuity.

Beyond direct input costs, tariff-driven trade frictions can affect timelines for equipment maintenance, the availability of spare parts, and cross-border collaboration on sample transfers. Contract research organizations and analytical laboratories that operate transnationally may face additional customs documentation and potential delays, which in turn influence study timelines and client relationships. Importantly, these dynamics encourage greater attention to nearshoring and supplier diversification as resilience strategies. As a result, strategic procurement, contractual flexibility, and enhanced logistics planning have become priorities for stakeholders aiming to mitigate the operational consequences of tariff-related disruptions while maintaining the scientific rigor required for pharmacokinetic analyses.

Detailed segmentation-driven insights revealing distinct analytical requirements and delivery models across product types, service approaches, and client profiles

Segmentation analysis reveals distinct pathways for service development and client engagement across product types, service modalities, and end-user categories. Based on Type, market is studied across Large Molecules Pharmacokinetics Services and Small Molecules Pharmacokinetics Services, which highlights divergent analytical demands: large molecules require immunoassay development, ligand-binding assays, and specialized sample handling to address stability and matrix effects, whereas small molecules often leverage high-resolution mass spectrometry and validated chromatographic methods. Based on Service Type, market is studied across In-Vitro and In-Vivo, illustrating that in vitro ADME and stability assays complement in vivo pharmacokinetic studies by informing early candidate selection and mechanistic understanding of clearance pathways. Based on End-User, market is studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, demonstrating that client needs vary from exploratory, hypothesis-driven investigations to fully regulated GLP-compliant studies with comprehensive documentation for regulatory submissions.

Taken together, these segmentation dimensions emphasize that providers must offer modular service stacks that accommodate high-sensitivity analytics for biologics, throughput-focused platforms for small molecules, and end-user-specific deliverables. Academic and government research institutes often prioritize methodological flexibility and novel assay development, biotechnology companies require agility and scientific partnership, contract research organizations focus on scalable operations and compliance, and large pharmaceutical companies demand integrated program management and regulatory-grade reporting. This segmentation-driven perspective underscores the necessity for customizable workflows, robust quality systems, and adaptable commercial models to serve a heterogeneous client base effectively.

Regional competitive advantages and operational considerations determining where pharmacokinetics service providers invest, collaborate, and scale globally

Regional dynamics shape service provision, infrastructure investment, and collaborative networks across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each offering unique competitive advantages and operational considerations. In the Americas, dense concentrations of biotechnology hubs and clinical development centers support rapid translational workflows and close provider-client interactions, while regulatory pathways and payer environments influence the emphasis on clinical pharmacology and data packages for North American sponsors. In Europe, Middle East & Africa, the regulatory mosaic and strong academic-research linkages encourage cross-border collaborations, multi-center studies, and harmonized assay validation to meet diverse jurisdictional expectations.

The Asia-Pacific region has expanded analytical capacity, driven by investment in laboratory infrastructure and a growing base of contract research capability; this growth supports cost-effective execution of high-volume bioanalysis and increasingly sophisticated work in biologics. Across regions, logistical considerations, sample transfer regulations, and local talent pools inform decisions about study design and outsourcing. Therefore, effective regional strategies blend proximity to clients, regulatory expertise, and supply chain resilience to deliver consistent, high-quality pharmacokinetic services while enabling global program execution and knowledge transfer.

Competitive dynamics favor providers that integrate advanced analytics, cross-disciplinary expertise, and client-centric commercial models to drive long-term partnerships

Leading companies in the pharmacokinetics services arena are evolving beyond transactional assay delivery to provide integrated scientific partnerships that span bioanalysis, modeling, and regulatory support. Successful firms differentiate through investments in platform automation, data integrity systems, and cross-functional teams that translate analytical output into actionable pharmacokinetic and pharmacodynamic interpretations. Strategic collaborations with instrument manufacturers and software vendors enhance analytical sensitivity and throughput, while internal development of standardized reporting templates accelerates regulatory submissions and client decision-making.

Moreover, companies are investing in talent development-combining analytical chemists, clinical pharmacologists, and modelers-to offer end-to-end program support. Commercially, flexible pricing models, bundled service offerings, and capacity guarantees are being used to align with client risk profiles and development timelines. Providers that demonstrate consistent quality, transparent audit readiness, and the ability to scale from early discovery to regulated clinical studies are most likely to retain long-term partnerships. In sum, the competitive landscape rewards organizations that pair scientific depth with operational excellence and client-centric service design.

Practical strategic priorities for service providers to strengthen scientific capabilities, operational resilience, and client-aligned commercial frameworks

Industry leaders should prioritize actionable changes that strengthen scientific capability, commercial resilience, and client alignment in the near term. First, investing in platform automation and robust bioanalytical workflows can reduce turnaround times and improve reproducibility, which is essential for maintaining competitiveness as therapeutic modalities diversify. Second, expanding modeling and simulation expertise within service teams enables providers to offer predictive insights that inform dose selection and trial design, thereby adding strategic value to client programs.

Third, diversifying supply chains and qualifying multiple reagent and equipment vendors mitigates risks from trade disruptions and tariff-related impacts. Fourth, developing flexible contracting frameworks and value-based pricing can align incentives with clients, particularly for biotechnology companies and sponsorship models that require iterative program adjustments. Finally, enhancing regulatory support services-including documentation readiness and clear modeling reports-helps clients navigate multi-jurisdictional submission requirements. Collectively, these initiatives will improve operational resilience, deepen scientific engagement, and position providers as indispensable partners in increasingly complex drug development pathways.

Transparent multi-method research approach combining expert interviews, literature synthesis, and scenario analysis to validate pharmacokinetics service trends and implications

The research methodology underpinning this analysis integrates qualitative expert interviews, subject-matter literature review, and a structured assessment of technological and regulatory trends. Primary insights were derived from conversations with pharmacokinetic scientists, clinical pharmacologists, laboratory operations leaders, and procurement specialists, ensuring a multi-perspective understanding of capabilities and constraints. Secondary research included peer-reviewed publications, regulatory guidance documents, and recent technical white papers to capture advancements in bioanalytical instrumentation, modeling approaches, and assay validation practices.

Analytical synthesis emphasized cross-validation of themes across sources to identify consistent patterns rather than isolated observations. Where applicable, operational impacts were evaluated through scenario analysis to assess supply chain sensitivity and the implications of evolving regulatory expectations. Throughout, careful attention was paid to ensuring methodological transparency, documenting assumptions, and identifying areas where further empirical investigation would be valuable for specialized program planning or procurement decisions.

Concluding synthesis of strategic imperatives for providers to align scientific innovation, operational resilience, and client-focused delivery in pharmacokinetics services

In conclusion, pharmacokinetics services occupy a central role in translating molecular discovery into safe and efficacious clinical strategies, and the sector is adapting to technological, modality, and geopolitical pressures. Providers that invest in advanced bioanalytical platforms, expand modeling and simulation capabilities, and build resilient supply chains will be best positioned to meet the diverse needs of academic sponsors, biotechnology firms, contract research organizations, and large pharmaceutical companies. Furthermore, regional dynamics and tariff-related considerations underscore the importance of flexible sourcing and nearshoring strategies to preserve timelines and data quality.

Looking ahead, closer integration of analytical output with predictive modeling, regulatory-focused documentation, and client-centric contracting will define provider differentiation. By pursuing the actionable recommendations outlined earlier, stakeholders can reduce development risk, accelerate translational milestones, and align service delivery with strategic program objectives. Continued collaboration across scientific, operational, and commercial functions will be essential to sustain innovation and reliability within the pharmacokinetics services ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmacokinetics Services Market, by Type

  • 8.1. Large Molecules Pharmacokinetics Services
  • 8.2. Small Molecules Pharmacokinetics Services

9. Pharmacokinetics Services Market, by Service Type

  • 9.1. In-Vitro
  • 9.2. In-Vivo

10. Pharmacokinetics Services Market, by End-User

  • 10.1. Academic & Government Research Institutes
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical Companies

11. Pharmacokinetics Services Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Pharmacokinetics Services Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Pharmacokinetics Services Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Pharmacokinetics Services Market

15. China Pharmacokinetics Services Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Absorption Systems LLC
  • 16.6. Allucent
  • 16.7. Aurigene Pharmaceutical Services Ltd.
  • 16.8. Certara
  • 16.9. Charles River Laboratories, Inc.
  • 16.10. Creative Bioarray
  • 16.11. Eurofins Scientific SE
  • 16.12. Evotec SE
  • 16.13. Frontage Laboratories, Inc.
  • 16.14. ICON PLC
  • 16.15. Laboratory Corporation of America Holdings
  • 16.16. LGC Limited by Cinven
  • 16.17. NUVISAN Pharma Holding GmbH
  • 16.18. Pacific BioLabs
  • 16.19. Parexel International (MA) Corporation
  • 16.20. Pfizer Inc.
  • 16.21. PPD Inc. by Thermo Fisher Scientific Inc.
  • 16.22. Premier Consulting
  • 16.23. Reaction Biology Corporation
  • 16.24. SGS SA
  • 16.25. Svar Life Science AB
  • 16.26. WuXi AppTec Co., Ltd.
  • 16.27. XenoTech by BioIVT
  • 16.28. Xyzagen

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 31. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 34. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 38. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 42. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 43. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 46. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 50. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 54. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 67. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 75. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)